Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

NCT01435369 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Malignant Melanoma

Interventions

DRUG: CT-011

Sponsor

Medivation, Inc.